Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Andrew Smith

Plastic Surgery Irvine, CA Medical Doctor

NPI 1174592778 CMS profile 144284

18 Endeavor Ste 102, Irvine, CA 92618

Open in the dashboard

General payments

$25,004

154 records reported · program years 2019–2025

Research payments

$1,313

Paid to them · 3 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Andrew Smith of Irvine, CA is reported in the CMS Open Payments database as having received $25,004 across 154 general payments and $1,313 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Plastic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $605 17
2024 General $373 22
2023 General $1,180 26
2022 General $325 15
2022 Research $375 1
2021 General $5,401 24
2021 Research $563 1
2020 General $367 19
2020 Research $375 1
2019 General $16,751 31

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andrew Smith
  • Plastic Surgery median
  • Middle half of Plastic Surgery
  • National median

In program year 2025, general payments to Andrew Smith were reported at $605. Among 3,701 Plastic Surgery profiles paid that year, the median was $379 and the middle half received between $138 and $1,100.

Show as a table
Year Andrew Smith Plastic Surgery median Middle half National median
2019 $16,751 $371 $122–$1,483 $163
2020 $367 $158 $52–$438 $114
2021 $5,401 $249 $87–$752 $132
2022 $325 $274 $102–$793 $149
2023 $1,180 $299 $113–$891 $160
2024 $373 $361 $124–$1,062 $164
2025 $605 $379 $138–$1,100 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Allergan Inc. $16,823 47 payments
  2. Johnson & Johnson Health Care Systems Inc. $4,725 2 payments
  3. Sientra, Inc. $1,731 30 payments
  4. AbbVie, Inc. $904 49 payments
  5. Mentor Worldwide LLC $193 3 payments
  6. Integra LifeSciences Corporation $124 5 payments
  7. Solta Medical, a division of Bausch Health US, LLC $106 3 payments
  8. Davol Inc. $105 4 payments
  9. Smith+Nephew, Inc. $86 4 payments
  10. Motiva USA, LLC $79 2 payments
  11. Other $127 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Gift $16,200 5 payments
  2. Debt forgiveness $4,725 2 payments
  3. Food and Beverage $3,329 143 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $750 4 payments
Products named General payments · program years 2019–2025
  1. NATRELLE $16,492 29 payments
  2. SIENTRA HIGH STRENGTH COHESIVE SILICONE GEL BREAST IMPLANT $1,731 30 payments
  3. NATRELLE SALINE-FILLED BREAST IMPLANTS Plastic Surgery $470 24 payments
  4. ALLODERM $284 18 payments
  5. NATRELLE SALINE-FILLED BREAST IMPLANTS Plastics $268 14 payments
  6. MENTOR MemoryGel Resterilizable Gel Sizer $193 3 payments
  7. Phasix Mesh $105 4 payments
  8. BOTOX $96 5 payments
  9. Santyl $86 4 payments
  10. Motiva Implant Matrix $79 2 payments
  11. Other $515 20 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Sientra, Inc. $1,313 3 payments

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

97

Median for Plastic and Reconstructive Surgery: 61

Drug cost

$679

Median for Plastic and Reconstructive Surgery: $369

Branded share of claims

40.2%

Median for Plastic and Reconstructive Surgery: 30%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Valacyclovir Valacyclovir Hcl Brand 15 $278
Cephalexin Generic 37 $210
Ondansetron Odt Ondansetron Brand 24 $136
Tramadol Hcl Generic 21 $55

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,638 Part D prescribers listed as Plastic and Reconstructive Surgery; they describe a distribution and say nothing about conduct.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $30
$30 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

157 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record